Longeveron (LGVN)
0.73
-0.07 (8.75%)
Upcoming Events
Latest Headlines
Longeveron CFO Lisa Locklear to step down in July
June 5, 2026 4:04 PM - StreetInsider
Form 8-K Longeveron Inc. For: Jun 01
June 5, 2026 4:01 PM - SEC Filing
Longeveron to Present at BIO International Convention 2026
June 4, 2026 9:15 AM - Globe NewsWire
Form ARS Longeveron Inc. For: Dec 31
May 20, 2026 4:13 PM - SEC Filing
Form DEFA14A Longeveron Inc.
May 20, 2026 4:12 PM - SEC Filing
Form DEF 14A Longeveron Inc. For: Jul 01
May 20, 2026 4:11 PM - SEC Filing
Longeveron CEO outlines strategy focused on partnerships and 2026 milestones
May 20, 2026 4:06 PM - StreetInsider
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
May 20, 2026 4:05 PM - Globe NewsWire
Form SCHEDULE 13G Longeveron Inc. Filed by: JANUS HENDERSON GROUP PLC
May 15, 2026 11:43 AM - SEC Filing
Longeveron (LGVN) Misses Q1 EPS by 19c
May 13, 2026 4:41 PM - StreetInsider
Form 8-K Longeveron Inc. For: May 13
May 13, 2026 4:15 PM - SEC Filing
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
May 13, 2026 4:05 PM - Globe NewsWire
Form 10-Q Longeveron Inc. For: Mar 31
May 13, 2026 4:02 PM - SEC Filing
Longeveron receives committee approval to complete stem cell trial
May 11, 2026 9:10 AM - StreetInsider
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
May 11, 2026 9:10 AM - Globe NewsWire
Maxim Group Downgrades Longeveron (LGVN) to Hold
May 11, 2026 7:44 AM - StreetInsider
Form 8-K Longeveron Inc. For: May 08
May 8, 2026 4:20 PM - SEC Filing
Longeveron meets with FDA on heart syndrome drug trial
May 8, 2026 4:05 PM - StreetInsider
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
May 8, 2026 4:05 PM - Globe NewsWire
Form 4 Longeveron Inc. For: May 01 Filed by: Blass Devin
May 5, 2026 6:00 PM - SEC Filing
Form 4 Longeveron Inc. For: May 01 Filed by: Willard Stephen H
May 5, 2026 6:00 PM - SEC Filing
Form 4 Longeveron Inc. For: May 01 Filed by: Agafonova Nataliya
May 5, 2026 6:00 PM - SEC Filing
Form 4 Longeveron Inc. For: May 01 Filed by: Lehr Paul T
May 5, 2026 6:00 PM - SEC Filing
Form 4 Longeveron Inc. For: May 01 Filed by: Locklear Lisa
May 5, 2026 6:00 PM - SEC Filing
Form PRE 14A Longeveron Inc. For: May 05
May 5, 2026 5:43 PM - SEC Filing
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
May 5, 2026 4:15 PM - Globe NewsWire
Longeveron (LGVN) PT Lowered to $8 at H.C. Wainwright
May 4, 2026 7:28 AM - StreetInsider
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
April 23, 2026 6:19 AM - StreetInsider
Form EFFECT Longeveron Inc.
April 20, 2026 6:04 AM - SEC Filing
Form 424B3 Longeveron Inc.
April 17, 2026 4:23 PM - SEC Filing
Form 8-K Longeveron Inc. For: Mar 25
April 10, 2026 4:49 PM - SEC Filing
Longeveron (LGVN) files for 30.9M share offering by selling stockholders
April 10, 2026 4:05 PM - StreetInsider
Form S-1 Longeveron Inc.
April 10, 2026 4:02 PM - SEC Filing
Longeveron receives Chinese patent for stem cell testing methods
April 8, 2026 9:15 AM - StreetInsider
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
April 8, 2026 9:15 AM - Globe NewsWire
Form 4 Longeveron Inc. For: Apr 01 Filed by: Lehr Paul T
April 3, 2026 5:01 PM - SEC Filing
Form 4 Longeveron Inc. For: Apr 01 Filed by: Locklear Lisa
April 3, 2026 5:00 PM - SEC Filing
Form 4 Longeveron Inc. For: Apr 01 Filed by: Agafonova Nataliya
April 3, 2026 5:00 PM - SEC Filing
Form 4 Longeveron Inc. For: Apr 01 Filed by: Willard Stephen H
April 3, 2026 5:00 PM - SEC Filing
Form 4 Longeveron Inc. For: Apr 01 Filed by: Blass Devin
April 3, 2026 5:00 PM - SEC Filing
Form 8-K Longeveron Inc. For: Mar 24
March 25, 2026 4:02 PM - SEC Filing
Form D Longeveron Inc.
March 25, 2026 10:14 AM - SEC Filing
Form 8-K Longeveron Inc. For: Mar 23
March 24, 2026 4:01 PM - SEC Filing
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
March 18, 2026 11:30 AM - StreetInsider
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
March 17, 2026 4:06 PM - Globe NewsWire
Form 10-K Longeveron Inc. For: Dec 31
March 17, 2026 4:01 PM - SEC Filing
Form 4 Longeveron Inc. For: Mar 02 Filed by: Willard Stephen H
March 13, 2026 8:59 PM - SEC Filing
Form 3 Longeveron Inc. For: Feb 11 Filed by: Willard Stephen H
March 13, 2026 8:59 PM - SEC Filing
Form 8-K Longeveron Inc. For: Mar 10
March 12, 2026 4:06 PM - SEC Filing
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
March 12, 2026 9:01 AM - Globe NewsWire
Longeveron closes $15 million private placement with potential $15 million more
March 11, 2026 4:05 PM - StreetInsider
Longeveron Announces Closing of Private Placement of up to $30 Million
March 11, 2026 4:05 PM - Globe NewsWire
Longeveron secures $30 million private placement for clinical trials
March 10, 2026 9:01 AM - StreetInsider
Longeveron Announces Private Placement of up to $30 Million
March 10, 2026 9:00 AM - Globe NewsWire
Form 8-K Longeveron Inc. For: Mar 03
March 9, 2026 6:01 AM - SEC Filing
Full Article List
